Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 15/20 | 0.48 |
| ▸ | EGFR | P00533 | 13/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.41 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4387060 | 1.00 | ERBB2 (0.48) | ERBB2EGFRKCNH2SLC6A2SLC6A4 | |
| SCHEMBL4389651 | 0.97 | ERBB2 (0.48) | ERBB2EGFRKCNH2SLC6A2SLC6A4 | |
| SCHEMBL4384923 | 0.97 | ERBB2 (0.48) | ERBB2EGFRKCNH2SLC6A2SLC6A4 | |
| SCHEMBL5490924 | 0.97 | ERBB2 (0.48) | ERBB2EGFRKCNH2SLC6A2SLC6A4 | |
| SCHEMBL4388217 | 0.89 | CHRNB2 (0.45) | ERBB2EGFRKCNH2 | |
| SCHEMBL4394507 | 0.89 | CHRNB2 (0.45) | ERBB2EGFRKCNH2 | |
| SCHEMBL4385024 | 0.87 | ERBB2 (0.43) | ERBB2EGFRKCNH2 | |
| SCHEMBL5696770 | 0.86 | EGFR (0.47) | ERBB2EGFRKCNH2EPHA2KDR | |
| SCHEMBL4393432 | 0.85 | EGFR (0.48) | ERBB2EGFRKCNH2EPHA2KDR | |
| SCHEMBL27669572 | 0.84 | EGFR (0.42) | ERBB2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664029-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-12-02 | — | — | EP | disclosed |
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
| EP-1664029-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026152-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ABL1, EGFR | ERBB2 1/4885EGFR 3/4885KCNH2 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.